Should You Follow Directors Buying At Monitise Plc, Hutchison China MediTech Limited And Tungsten Corp PLC?

Is it time to invest in Monitise Plc (LON:MONI), Hutchison China MediTech Limited (LON:HCM) and Tungsten Corp PLC (LON:TUNG) after big director buys?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Directors have been buying shares with a vengeance at Monitise (LSE: MONI), Hutchison China MediTech (LSE: HCM) and Tungsten (LSE: TUNG).

Is the time ripe for investors to follow the lead of the directors, and buy into these three companies?

Monitise

AIM-listed mobile money firm Monitise put itself up for sale in January. However, two weeks ago this £300m company said that none of the proposals it had received “fully recognised the longer-term value of Monitise”, and that the company would continue as an independent entity.

At the same time, Monitise announced a boardroom shake-up, which included founder and co-CEO Alastair Lukies stepping down, and co-CEO Elizabeth Buse becoming sole CEO. Last week, the directors were buying en masse.

Director No. of shares Price per share Total investment
Elizabeth Buse (CEO) 500,000 13.25p £66,250
Lee Cameron (Deputy CEO) 250,000 13.25p £33,125
(Spouse of) Tim Wade (Non-exec) 250,000 14.14p £35,350
Colin Tucker (Non-exec) 100,000 14.19p £14,190

Personally, I’m not convinced the levels of these buys represent anything more than a “show” of confidence. Monitise still has to prove it can make money from its impressive blue-chip roll-call of strategic investors, channel partners and clients such as Santander, MasterCard, IBM and Royal Bank of Scotland. Potentially, though, the rewards could be huge — even for those punting today at a higher price (15.75p) than the directors bought at.

Tungsten

Founded by City financier Edmund Truell, Tungsten describes itself as “a leading provider of automated invoice processing, supply chain finance and spend analysis”. Like Monitise, Tungsten has an impressive array of blue-chip clients, including GlaxoSmithKline, Unilever and Aviva. Also like Monitise, Tungsten is currently loss-making.

Investors are divided about this £220m company. On one hand, there is some heavyweight institutional support on the shareholder register — notably Odey Asset Management — but, on the other, Tungsten is reportedly the most heavily shorted stock on the AIM market.

Founder and CEO Edmund Truell has backed his company to the hilt, recently adding to his already-substantial shareholding. Between 27 February and 31 March, Truell purchased 1.59 million shares in six tranches at a cost of £2.73m. He bought at prices between 147p and 201p a share, with the average working out at 172p. If you want to take a punt on Tungsten, the shares are trading at 198p, as I write.

Hutchison China MediTech

Hutchison China MediTech — or, Chi-Med as it refers to itself — is the eighth-largest company on the AIM market, valued at £730m. Chi-Med has a drug R&D division and a consumer healthcare division, and has partnerships with blue-chip giants, including AstraZeneca, Eli Lilly and Johnson & Johnson. And guess what? Chi-Med is actually profitable. Hurrah!

Sure, the P/E may be high at 75 times current-year forecast earnings, but the company’s pipeline has the potential to yield multiple new drug approvals. The high P/E hasn’t put off Chairman Simon To and non-exec director Edith Shih, who’ve both bought several tranches of shares between 30 March and 7 April, paying between 1,300p and 1,385p a share. To has invested over £1m and Shih over £0.5m. If you want to follow suit, Chi-Med’s shares are currently trading at 1,392p.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended shares in GlaxoSmithKline, and owns shares of Monitise and Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »